Editors' picks from other sources

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Prevention of mother-to-child transmission news

Show

From To
Access to medicines and treatment
Kenya: 69,000 newborns at risk due to ARVs shortage

Medical personnel at several public hospitals who spoke to the Nation on the condition of anonymity said the shortage began about four months ago. They said the situation is dire, and that if no intervention is made urgently, things could turn disastrous. The administration of ARVs to newborns without HIV is meant to reduce the risk of mother-to-child transmission (perinatal acquisition).

Published
24 June 2019
From
The Nation
Side-effects
A Promising Anti-HIV Drug Poses A Dilemma

The anti-HIV drug dolutegravir is effective — but may carry a risk for pregnant women. While women in wealthy countries are given choices about their medical care, for women in poor countries the situation is different. There aren't enough doctors and nurses to explain the risks and benefits of the new drug to every patient. The country may not have the resources to keep supplies of two different drugs on the shelves. And there is no consistent access to effective birth control.

Published
23 April 2019
From
NPR
Prevention of mother-to-child transmission
Elvitegravir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1

Pharmacokinetic data indicate exposure of elvitegravir boosted with cobicistat (Genvoya, Stribild) is lower during the second and third trimesters of pregnancy than postpartum. Low elvitegravir exposure may be associated with an increased risk of treatment failure and an increased risk of HIV-1 transmission to the unborn child, and therefore elvitegravir/cobicistat should not be used during pregnancy.

Published
17 April 2019
From
Medicines and Healthcare products Regulatory Agency
Treatment guidelines
Avoiding Dolutegravir in Young Women With HIV: Time for a Rethink?

Total deaths for women with HIV and their children are projected to be lower with dolutegravir-based (Tivicay) antiretroviral therapy (ART) versus efavirenz-based (Sustiva) ART, a model-based analysis found.

Published
05 April 2019
From
MedPage Today
Adherence
'Vast majority' of elevated viral load episodes in pregnant women caused by non-adherence

Non-adherence to ART — and not pretreatment drug-resistant mutations — explain the “vast majority” of elevated viral load episodes in women initiating ART during pregnancy, according to results from a study conducted in South Africa.

Published
02 April 2019
From
Healio
The search for an HIV prevention vaccine
HIV antibody VRC01LS safe prevention strategy for infants

Subcutaneous doses of a broadly neutralizing monoclonal antibody, known as VRC01LS, given at birth and 12 weeks were well-tolerated by HIV-exposed infants, according to the results of an open-label safety and pharmacokinetic study presented at the Conference on Retroviruses and Opportunistic Infections. Researchers are studying VRC01LS in combination with ART to prevent HIV infection in neonates.

Published
12 March 2019
From
Healio
TB transmission and prevention
Tshepiso study: Preventive TB therapy not associated with poor pregnancy outcomes

Initiating isoniazid preventive therapy for tuberculosis during pregnancy is not associated with a higher rate of poor maternal or infant outcomes, according to observational results from the Tshepiso study presented at CROI.

Published
12 March 2019
From
Healio
Achieving the 90-90-90 target
CROI 2019: Thailand’s strides spanned HIV treatment, prevention and research

he first HIV vaccine trials to yield signs of hope happened here. Thailand was also the first Asian country to eliminate mother-to-child transmission of HIV. Now, Thailand has achieved the first part of UNAIDS’ 90-90-90 targets: 98 percent of people infected with HIV know their status.

Published
06 March 2019
From
Science Speaks
Child developmental issues
South Africa urgently needs an antiretroviral pregnancy registry

With the dolutegravir roll-out around the corner, the time is now ripe for patients and activists to demand a prospective pregnancy registry for the whole of South Africa. Whether it is a new endeavour or piggy-backs on international efforts is a matter for debate, but it is the only way we can answer the question of dolutegravir’s safety with the minimum number of women being exposed to the drug. It’s the least that patients deserve.

Published
29 January 2019
From
Spotlight
Bad science and bogus treatments
As A Strategy for HIV Prevention, Disabling the CCR5 Gene in Embryos Implanted in HIV-Negative Mothers Makes Zero Sense

Here are a bunch of things we know about HIV prevention. You’ll note that nowhere on this list is anything about preventing HIV in babies born to women who don’t have the virus to begin with — because the babies are not at risk, even if the mother’s male sexual partner has HIV.

Published
03 December 2018
From
NEJM Journal Watch
← First12345...25Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.